Ashkan Shoamanesh Shares OCEANIC-STROKE Trial’s Successful Endpoints
Ashkan Shoamanesh, Associate Professor of Medicine (Neurology), Marta and Owen Boris Chair in Stroke Research and Care at McMaster University, shared on LinkedIn:
”We are absolutely thrilled to share that the OCEANIC-STROKE trial has successfully met its primary efficacy and safety endpoints.
These landmark findings validate our ability to uncouple pathological thrombus formation from hemostasis—a breakthrough that has the potential to have far more reaching impact in the medical care of patients with cardiovascular disease.
Asundexian now emerges as an established treatment option addressing a major unmet need among the approximately 5 million people worldwide who experience a new non-cardioembolic ischemic stroke each year.
We are profoundly grateful for our partnership with Bayer and for the invaluable contributions of our global network of investigators and study teams whose dedication made OCEANIC-STROKE possible.”
Read the full article here.
Stay updated with Hemostasis Today.
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia
-
Aug 23, 2026, 16:03Balaji Balagani: Major Causes of Sudden Cardiac Death in Children
-
Aug 23, 2026, 16:02Bartosz Hudzik: What’s Hot at ESC Congress 2026